Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 322-332

  Tang, Yong ^a   Hamed, Hossein A ^a   Poklepovic, Andrew ^a   Dai, Yun ^a   Grant, Steven ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; CHECKPOINT KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; VELIPARIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION;

ANIMALS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863970298     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.078907     Document Type: Article

References (50)

1. Amé JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, Muller S, Höger T, Ménissier-de Murcia J, and de Murcia G (1999) PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 274:17860-17868.
2. Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, and Sebolt-Leopold JS (1991) Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res 126:367-371.
3. Bartek J and Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429.
4. Ben-Hur E, Chen CC, and Elkind MM (1985) Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res 45:2123-2127.
5. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, and Durkacz BW (1995) Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 72:849-856.
6. Bowman KJ, Newell DR, Calvert AH, and Curtin NJ (2001) Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84:106-112.
7. Bowman KJ, White A, Golding BT, Griffin RJ, and Curtin NJ (1998) Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 78:1269-1277.
8. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, and Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917.
9. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D (2007) Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Can Ther 6:935-944.
10. Carrassa L, Broggini M, Erba E, and Damia G (2004) Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 3:1177-1181.
11. Cho SH, Toouli CD, Fujii GH, Crain C, and Parry D (2005) Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 4:131-139.
12. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
13. Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, and Grant S (2008) Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112:2439-2449.
14. Dai Y, Landowski TH, Rosen ST, Dent P, and Grant S (2002) Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 100:3333-3343.
15. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P, and Grant S (2001) Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/ MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61:5106-5115.
16. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, and Newell DR (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6:2860-2867.
17. Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, and Grant S (2011) CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 11:133-140.
18. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, et al. (2007) ABT-888, an orally active poly- (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728-2737.
19. Eymin B, Claverie P, Salon C, Brambilla C, Brambilla E, and Gazzeri S (2006) p14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation. Cell Cycle 5:759-765.
20. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al. (2006) Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66:11954-11966.
21. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921.
22. Fernandez-Capetillo O, Lee A, Nussenzweig M, and Nussenzweig A (2004) H2AX: the histone guardian of the genome. DNA Repair 3:959-967.
23. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134.
24. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, and Valerie K (2007) Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 67:1046-1053.
25. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, and Piwnica- Worms H (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605.
26. Graziani G and Szabó C (2005) Clinical perspectives of PARP inhibitors. Pharmacol Res 52:109-118.
27. Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, et al. (2008) Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther 7:616-629.
28. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, et al. (2011) A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 104:750-755.
29. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, and Van Aalten DM (2003) Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 375:255-262.
30. Lee JH and Paull TT (2007) Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26:7741-7748.
31. 2 checkpoint due to over-activated CHK1 in the absence of PARP-1. Cell Cycle 5:2364-2370.
32. Lukas C, Falck J, Bartkova J, Bartek J, and Lukas J (2003) Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 5:255-260.
33. Martin SA, Lord CJ, and Ashworth A (2008) DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18:80-86.
34. Mitchell C, Park M, Eulitt P, Yang C, Yacoub A, and Dent P (2010a) Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Mol Pharmacol 78:909-917.
35. Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, and Dent P (2010b) Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 10:903-917.
36. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, and Maybaum J (2006) The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 5:1983-1988.
37. 2checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70:4972-4981.
38. Mow BM, Blajeski AL, Chandra J, and Kaufmann SH (2001) Apoptosis and the response to anticancer therapy. Curr Opin Oncol 13:453-462.
39. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, and Piwnica-Worms H (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501-1505.
40. Prudhomme M (2006) Novel checkpoint 1 inhibitors. Recent Pat Anticancer Drug Discov 1:55-68.
41. Riches LC, Lynch AM, and Gooderham NJ (2008) Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 23:331-339.
42. Rodon J, Iniesta MD, and Papadopoulos K (2009) Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 18:31-43.
43. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, and Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301.
44. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, and Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39-85.
45. Schreiber V, Amé JC, Dollé P, Schultz I, Rinaldi B, Fraulob V, Ménissier-de Murcia J, and de Murcia G (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277:23028-23036.
46. Tentori L, Portarena I, and Graziani G (2002) Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 45:73-85.
47. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244.
48. Weltin D, Holl V, Hyun JW, Dufour P, Marchal J, and Bischoff P (1997) Effect of 6(5H)-phenanthridinone, a poly (ADP-ribose)polymerase inhibitor, and ionizing radiation on the growth of cultured lymphoma cells. Int J Radiat Biol 72:685-692.
49. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966.
50. Zhao H, Watkins JL, and Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 99:14795-14800.